Previous 10 | Next 10 |
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone The partnership combines CureVac's mRNA technology with myNEO's platform for the discovery and selection of tumor antigens predicted to elicit strong immune responses ...
Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influenza clinical trial ...
Image source: The Motley Fool. CureVac (NASDAQ: CVAC) Q1 2022 Earnings Call Apr 28, 2022 , 9:00 a.m. ET Operator Continue reading For further details see: CureVac (CVAC) Q1 2022 Earnings Call Transcript
CureVac NV (CVAC) Q4 2021 Earnings Conference Call April 28, 2022, 09:00 ET Company Participants Sarah Fakih - VP Corporate Communications & IR Franz-Werner Haas - CEO Klaus Edvardsen - Chief Development Officer Pierre Kemula - CFO Conference Call Participants Douglas Buchanan - JMP Secur...
CureVac BV press release (NASDAQ:CVAC): Q4 Pre-tax loss of €4.5M. Revenue of €41.2M (+586.7% Y/Y). Cash and cash equivalents decreased to €811.5 million as of December 31, 2021, from €1,322.6 billion as of December 31, 2020. Shares -1.19% PM. ...
- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone - Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, validating mRNA backbone for further variant ada...
ABG,ABMD,AEP,AIT,ALNY,AOS,ARES,ASPN,ASPS,ASX,OTCPK:ATGFF,BAX,BC,BCS,BFH,BTU,CARR,CAT,OTCPK:CDUAF,CFR,CG,CHD,CMCSA,CNX,CRS,CVAC,CWT,CX,CYBE,DPZ,DTE,EME,ERJ,FAF,FBP,FCN,FCNCA,FLWS,OTCQB:FMCC,FTV,GLOP,GLYC,GOL,GTX,GVA,GWW,HSY,HUN,HZO,ICLR,IP,IPG,IRM,JKS,KBR,KDP,KEX,KIM,LAZ,LECO,LH,LIN,LKQ,LLNW,L...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / April 22, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and provide business updates for the...
CureVac (NASDAQ:CVAC) shares are trading higher in the pre-market Thursday after the German biotech announced promising pre-clinical data for a second-generation bivalent COVID-19 vaccine candidate it jointly develops with GlaxoSmithKline (NYSE:GSK). In the study, the animals were immunized o...
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study - Demonstrated neutralizing capacity against the Omicron variant in vaccinated animals - Technology adaptation for bivalent approach for COVI...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...